Uniqure readies share stock offering
Dutch Uniqure BV launched a public offering of five million shares of common stock. Underwriters over-allotment will be an additional 750,000 shares.
Voluntary health agency jump-starts Selvitas SEL120 programme
The Leukemia & Lymphoma Society (LLS) and Polish drug developer Selvita SA have entered a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients with acute myeloid leukaemia (AML).
Uniqures new COO to oversee GMP
Gene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current Good Manufacturing Process (cGMP) activities and all product development functions.
Hansas immunomodulatory enzyme does the job
Sweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection.
J&J intensifies vaccine endeavour with Bavarian Nordic
Johnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.
GSK cancels 30 preclinical and clinical programmes
UKs biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and HIV/infectious diseases) and two potential (Oncology and Immuno-inflammation) priority areas.
Ablynx adds Sanofi to its list of pharma partners
Belgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth 2.4bn but comes with an upfront payment of just 23m. The partners will initially focus on therapeutics for the treatment of various immune-mediated inflammatory diseases.
Seventure debuts in Japan with microbiome investment
Venture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventures Health for Life Capital investment vehicle.